I have known ALXN for a very long time. Their initial project was Post Cardiotomy syndrome for CAGB patient and PG was partner with them. Project failed and PG moved away from them. Eclizumab was not a major project for them but look how it turn out for the company and investors. Stock use to be only $18 dollars, not many years ago.
REGN used to work on Obesity but something else i.e anti VGEF worked for them and now they are working on lowering LDL. Same way it used to trade at $18-22.
I still think VRTX has better projects and it is just matter of time that this giant volcano will errupt. I am wishing that Kalydeco sales will exceed $75 M in Q2. Chances are high that people will use it off label.